List of Excipients in Branded Drug VAGISTAT

Generic Drugs Containing VAGISTAT

Company	Ingredient	NDC	Excipient
Combe Incorporated	tioconazole	11509-0426	BUTYLATED HYDROXYANISOLE
Combe Incorporated	tioconazole	11509-0426	MAGNESIUM ALUMINUM SILICATE
Combe Incorporated	tioconazole	11509-0426	PETROLATUM

What are the Most Frequently-Used Excipients in VAGISTAT?

# Of NDCs	Excipient
1	BUTYLATED HYDROXYANISOLE
1	MAGNESIUM ALUMINUM SILICATE
1	PETROLATUM

VAGISTAT Excipient Strategy and Commercial Opportunities

Last updated: August 11, 2026

VAGISTAT is best analyzed as Vagistat-1, an over-the-counter vaginal tioconazole 6.5% ointment. Its commercial value is unlikely to come from new chemical-entity exclusivity. The stronger opportunities are differentiated dosage forms, improved excipient tolerability, applicator design, leakage control, and retail positioning against miconazole products and prescription azole therapies.

The product has a mature active ingredient, limited apparent molecule-level patent leverage, and a regulatory pathway centered on FDA over-the-counter vaginal antifungal requirements. A successful reformulation must preserve tioconazole solubility, vaginal residence, microbiological quality, applicator performance, and the established 1-dose consumer proposition.

What is VAGISTAT and which dosage form does it use?

Vagistat-1 contains tioconazole 6.5% in a vaginal ointment supplied with a single-use applicator. Tioconazole is an imidazole antifungal used for vulvovaginal candidiasis. The product is marketed for intravaginal administration and is positioned as a single-dose alternative to multi-day miconazole regimens.[1]

Attribute	Vagistat-1
Active ingredient	Tioconazole
Strength	6.5%
Dosage form	Vaginal ointment
Route	Intravaginal
Treatment duration	Single administration
Regulatory category	OTC vaginal antifungal
Primary therapeutic comparator	Miconazole vaginal products
Main commercial constraint	Mature generic and private-label competition

The excipient system is commercially important because tioconazole is a lipophilic drug. The vehicle must maintain uniform drug distribution while permitting administration, vaginal spreading, retention and release at the mucosal surface.

What excipients are used in VAGISTAT?

Public product labeling identifies VAGISTAT as a tioconazole vaginal ointment. The relevant formulation strategy is a semisolid vehicle designed to deliver a poorly water-soluble imidazole directly to the vaginal mucosa.[1]

Public labels for OTC vaginal products do not always disclose formulation development details such as drug particle size, polymorphic form, rheology targets, release specifications or manufacturing order of addition. Those parameters can materially affect product performance even when the listed inactive ingredients appear similar.

The principal excipient functions are:

Excipient function	Commercial and technical purpose
Ointment vehicle	Solubilizes or disperses tioconazole and supports vaginal delivery
Emollient or lipid phase	Improves spreading and reduces mechanical discomfort
Surfactant	Stabilizes the drug-containing semisolid and improves wetting
Thickener or structurant	Controls viscosity, leakage and applicator discharge
Preservative, where applicable	Controls microbial risk in formulations containing water
pH modifier	Maintains product stability and mucosal tolerability
Antioxidant, where applicable	Limits oxidative degradation of drug or excipients
Purified water, where applicable	Supports emulsion structure or hydrophilic excipient phase

For a reformulation, the key issue is not the number of excipients. It is whether the vehicle produces reproducible dose delivery and an acceptable balance between retention and clean removal.

Which excipient properties matter most for tioconazole vaginal products?

Tioconazole’s lipophilicity favors a nonaqueous or emulsion-based delivery system. The principal development risks are incomplete drug release, phase separation, poor dose uniformity, excessive leakage and irritation from surfactants or preservatives.

Solubility and drug distribution

A formulation can deliver tioconazole as a true solution, a suspension, or a combination of dissolved and dispersed drug. Each approach has different risks.

A solution may improve content uniformity but can require high concentrations of solvents or surfactants. A suspension may reduce solvent exposure but requires control of particle size, sedimentation and redispersion. For a single-use semisolid, the manufacturing process must ensure that every applicator receives the labeled dose.

Rheology and leakage

The ideal product should be firm enough to remain in place after administration but soft enough to pass through the applicator without excessive force. Yield stress, viscosity at body temperature and shear recovery are important product attributes.

A formulation that is too fluid can leak and create poor consumer perception. A formulation that is too stiff can cause incomplete discharge or discomfort. Temperature sensitivity also matters because products may be stored in bathrooms, vehicles or warehouses with substantial seasonal variation.

Vaginal tolerability

Excipient selection should prioritize low irritation potential. Fragrances, unnecessary essential oils, aggressive surfactants and high concentrations of volatile solvents are poor fits for a vaginal antifungal product.

The formulation should be evaluated for:

• Local irritation and sensitization
• Impact on vaginal epithelial integrity
• Osmolality
• pH after dilution with vaginal fluid
• Compatibility with latex and nonlatex contraceptive materials
• Effects on vaginal microbiota
• Residual burning or discharge after treatment

The product label should not imply microbiome restoration unless supported by clinical data. Vaginal candidiasis products are regulated and marketed primarily for antifungal treatment, not microbiome modification.

What formulation opportunities could improve VAGISTAT?

The highest-value opportunities involve delivery performance rather than a simple excipient substitution.

Low-leakage mucoadhesive ointment

A modified semisolid could use a controlled amount of a mucoadhesive polymer, such as a cellulosic polymer or compatible polyacrylate, to increase residence time. The main design risk is excessive adhesion, clumping or delayed clearance.

The strongest commercial positioning would be:

• Less leakage after administration
• Lower need for pads or liners
• More consistent overnight retention
• Single-dose convenience with improved comfort

The formulation must avoid creating a dense film that limits tioconazole release.

Thermoresponsive gel

A poloxamer-based system could be engineered to remain administrable at room temperature and thicken after exposure to body temperature. This approach could reduce leakage and improve retention.

The main technical risks are:

• High polymer concentration and poor applicator flow
• Sensitivity to storage temperature
• Incomplete drug solubilization
• Mucosal cooling or discomfort
• Difficulty maintaining dose uniformity

A thermoresponsive product could support meaningful differentiation, but it would likely require more extensive formulation and clinical bridging than a conventional ointment.

Vaginal ovule or pessary

A solid or semisolid ovule could improve portability and reduce packaging volume. Lipid, polyethylene glycol or polymeric bases are possible platforms.

The commercial disadvantages include:

• Potential residue
• Longer dissolution time
• Greater sensitivity to storage temperature
• More complicated manufacturing
• Consumer preference differences between applicator-delivered ointment and insertable solid dosage forms

An ovule is more attractive as a separate product line than as a low-cost replacement for the current formulation.

Water-based emulsion

A water-continuous emulsion could provide a less greasy sensory profile. It may be easier for consumers to wash away and could reduce the perception of heavy residue.

The development burden is higher because the formulation must address:

• Preservative effectiveness
• Microbial control
• Emulsion stability
• Tioconazole partitioning
• Packaging compatibility
• Potential irritation from surfactants and preservatives

A water-based system could support a "clean feel" claim, but such claims require carefully controlled consumer and clinical testing.

Applicator redesign

The applicator may offer a faster route to differentiation than a new excipient system. Opportunities include:

• Lower discharge force
• Reduced residual volume
• Better ergonomic handling
• Tamper-evident unit-dose packaging
• Applicators optimized for limited dexterity
• More discreet packaging
• Improved compatibility with the formulation vehicle

Device changes can create commercial value without materially changing the active ingredient. They also can create patentable design or combination-device claims, although enforceability depends on claim scope and prosecution history.

How does VAGISTAT compare with miconazole vaginal products?

VAGISTAT competes mainly with miconazole products such as 1-day, 3-day and 7-day vaginal regimens. The key differentiator is the single-dose tioconazole format.

Commercial factor	Tioconazole 6.5% VAGISTAT	Miconazole vaginal products
Typical consumer proposition	Single-dose treatment	Multiple treatment durations
Formulation platforms	Ointment and potential semisolid variants	Creams, suppositories and ovules
Main perceived advantage	Convenience	Range of price and duration options
Main consumer concern	Messiness or leakage	Treatment duration and residue
Retail competition	Private-label and branded OTC products	Broad branded and private-label competition
Formulation opportunity	Low-leakage, clean-feel, mucoadhesive delivery	Better short-course adherence and comfort

Miconazole has greater shelf presence across dosage forms, while tioconazole can compete through convenience. A reformulated VAGISTAT product should avoid competing solely on price against retailer-controlled generic products.

What FDA regulatory pathway applies to VAGISTAT reformulation?

VAGISTAT is an OTC vaginal antifungal product. Products in this category must comply with the applicable FDA OTC antifungal framework, including active ingredient, concentration, labeling, dosage form, directions, warnings and manufacturing requirements.[2]

A reformulation can fall into different regulatory categories:

Change	Likely regulatory significance
Same active, same strength, minor inactive-ingredient adjustment	May be manageable within OTC requirements if all conditions remain satisfied
New dosage form	May require a different regulatory justification and additional data
New delivery device	Requires device and drug compatibility assessment
New indication or dosing schedule	Likely requires FDA review beyond a simple formulation change
New combination active ingredient	Requires separate regulatory analysis
New clinical claim	Requires substantiation and potentially a new application pathway

The commercial team should treat changes to dosage form, dose delivery, treatment duration and consumer claims as higher-risk than ordinary excipient substitutions.

What patents protect VAGISTAT and how strong is the patent estate?

VAGISTAT’s commercial protection is expected to rely more on brand, formulation know-how, packaging and channel execution than on active-ingredient patents.

Tioconazole is an established imidazole antifungal. The likely commercial barriers are:

1. Regulatory compliance for OTC vaginal antifungal products.
2. Manufacturing know-how for a stable, uniform semisolid.
3. Trade secrets involving mixing, filling and temperature control.
4. Device and applicator design.
5. Trademark and brand recognition.
6. Retail distribution and shelf placement.

Orange Book status

The Orange Book is primarily relevant to approved prescription and certain listed drug products. OTC monograph products do not generally receive the same patent-listing and Paragraph IV framework associated with an NDA-listed prescription product.[3]

As a result, an OTC VAGISTAT reformulation is unlikely to obtain meaningful exclusivity merely from using a new excipient unless the product is pursued through a regulatory pathway that supports product-specific intellectual-property protection.

Formulation patent potential

Potential patent claims could cover:

• Tioconazole concentration ranges in a defined vehicle
• Specific lipid, polymer or surfactant combinations
• Rheological properties at defined temperatures
• Low-leakage vaginal delivery systems
• Mucoadhesive compositions
• Unit-dose applicators
• Drug-device combinations
• Manufacturing processes that produce defined particle-size or uniformity profiles

The patent estate would be strongest if it linked a narrow composition to measured performance advantages, such as improved retention, reduced leakage, faster drug release or lower irritation. Broad claims covering ordinary ointment excipients would face substantial validity and freedom-to-operate pressure.

When does VAGISTAT lose exclusivity?

VAGISTAT does not have a conventional near-term patent-cliff profile comparable to a recently approved prescription drug. Its relevant exclusivity is commercial and regulatory rather than a single identifiable compound patent expiration date.

Exclusivity category	VAGISTAT position
New chemical entity exclusivity	Not relevant to established tioconazole
Prescription drug exclusivity	Not the principal commercial model
OTC monograph protection	Product must comply with applicable monograph conditions
Brand protection	Trademark and consumer recognition
Formulation protection	Possible for new, non-obvious compositions
Device protection	Possible for novel applicator systems
Trade-secret protection	Likely important for process and quality control

The principal generic-entry risk is already present. Competitors can launch comparable tioconazole or alternative azole products if they satisfy the applicable FDA requirements and obtain appropriate market access.

Which companies are challenging VAGISTAT commercially?

The relevant competitive set includes:

• Branded miconazole manufacturers
• Private-label OTC vaginal antifungal suppliers
• Generic pharmaceutical companies
• Retail pharmacy and mass-market private-label programs
• Prescription manufacturers of terconazole and other azole therapies

Commercial competition is more likely to arise from retail substitution than from Paragraph IV litigation. A retailer can replace branded VAGISTAT shelf space with lower-priced miconazole or private-label products without directly challenging a patent estate.

What manufacturing and intellectual-property barriers exist?

The manufacturing barrier is moderate. Standard semisolid production is accessible to many contract manufacturers, but vaginal products have specific quality risks.

Key manufacturing controls include:

• Homogeneous tioconazole distribution
• Control of particle size if the drug is suspended
• Temperature-controlled mixing
• Prevention of phase separation
• Accurate unit-dose filling
• Applicator fill-weight consistency
• Container-closure compatibility
• Microbial and preservative control
• Stability under accelerated and long-term conditions

The most defensible know-how may reside in process parameters rather than excipient identity. A company that can demonstrate consistent release and low leakage across temperature ranges may achieve a stronger product position than one that merely changes the vehicle.

What licensing opportunities exist for VAGISTAT?

Potential licensing opportunities fall into four categories.

Excipient and delivery-platform licensing

A company with a validated mucoadhesive, thermoresponsive or low-residue vaginal platform could license the technology to an OTC manufacturer. The licensing package would be stronger if it included stability data, mucosal tolerability data and scale-up experience.

Applicator licensing

A ready-to-commercialize unit-dose applicator can reduce development time and support a device-focused product story. Compatibility with lipid and emulsion vehicles is essential.

Brand and private-label licensing

VAGISTAT’s brand could support co-branding, retailer-specific packaging or regional distribution agreements. The value depends on current brand recognition, channel access and whether the licensee can obtain favorable manufacturing economics.

Geographic licensing

Regulatory classification for vaginal tioconazole products differs by country. A U.S. OTC product may require separate registration, labeling and clinical support in other jurisdictions. Licensing partners with local regulatory infrastructure could support expansion into Canada, Europe, Latin America and selected Asia-Pacific markets.

What revenue opportunities exist for a VAGISTAT reformulation?

The strongest revenue opportunities are premium OTC segments rather than broad price competition.

Opportunity	Revenue logic	Development burden
Low-leakage single-dose ointment	Premium over standard generic products	Low to moderate
Clean-feel water-based formulation	Appeals to sensory-sensitive consumers	Moderate
Thermoresponsive gel	Supports differentiated delivery claims	Moderate to high
Improved applicator	Adds convenience without changing active	Low to moderate
Travel or discreet unit-dose pack	Expands convenience and impulse purchase	Low
Private-label platform	Increases manufacturing volume	Low to moderate
Combination antifungal product	Broadens consumer proposition	High regulatory risk
Pediatric or pregnancy-focused positioning	Potentially valuable but clinically sensitive	High

A premium product should be supported by measurable endpoints. Consumer preference alone may not justify a substantial price premium if the product remains therapeutically interchangeable with low-cost miconazole.

What generic launch scenarios exist for VAGISTAT?

Three launch scenarios are commercially realistic.

Scenario 1: Direct low-cost equivalent

A competitor launches a conventional tioconazole semisolid or another OTC vaginal azole. Price and retailer access determine share. This scenario creates the greatest pressure on an undifferentiated VAGISTAT product.

Scenario 2: Formulation-led premium entry

A competitor launches a cleaner, lower-leakage or more convenient product. This could take share without being therapeutically superior if consumers value comfort and convenience.

Scenario 3: Retailer private-label substitution

A retailer replaces branded product inventory with private-label miconazole or tioconazole. This scenario can reduce branded revenue even without patent litigation or regulatory challenge.

The best defense is a differentiated product with a clear consumer benefit, protected manufacturing knowledge and a strong distribution agreement.

Key Takeaways

• VAGISTAT is best understood as Vagistat-1, a single-dose tioconazole 6.5% vaginal ointment.
• Its commercial opportunity is formulation and delivery differentiation, not active-ingredient exclusivity.
• The highest-value excipient objectives are low leakage, adequate vaginal residence, rapid drug release and low irritation.
• Mucoadhesive, thermoresponsive, water-based and ovule platforms are viable but carry increasing development and regulatory burdens.
• Applicator redesign may offer the fastest path to meaningful differentiation.
• OTC monograph compliance, rather than Orange Book patent listing, is central to regulatory strategy.
• Generic and private-label competition are immediate risks.
• Formulation patents are potentially valuable only when tied to non-obvious compositions and measurable performance.
• Licensing opportunities exist in excipient platforms, applicators, private-label manufacturing and regional distribution.
• A premium reformulation requires clinical, sensory or usability evidence that consumers recognize as materially better than inexpensive miconazole products.

FAQs

Is VAGISTAT a prescription drug or an over-the-counter product?

Vagistat-1 is marketed as an OTC vaginal antifungal containing tioconazole 6.5%.

Can a new excipient create exclusivity for VAGISTAT?

A new excipient alone rarely creates meaningful exclusivity. Protection is stronger when the excipient is part of a novel composition, delivery system or manufacturing process supported by measurable performance advantages.

Is tioconazole compatible with latex condoms?

Vaginal antifungal products can affect the integrity or reliability of latex contraceptive materials. Product-specific labeling and compatibility testing control the commercial claim.

Would a water-based VAGISTAT formulation be superior to the current ointment?

It could improve washability and sensory acceptance, but it would introduce additional risks involving preservation, emulsion stability, drug partitioning and mucosal tolerability.

Is biosimilar competition relevant to VAGISTAT?

No. Tioconazole is a small-molecule antifungal. The relevant competitive risks are generic, private-label and reformulated OTC products, not biosimilars.

References

1. DailyMed. (n.d.). Vagistat-1: Tioconazole 6.5% vaginal ointment, drug labeling. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Over-the-counter antifungal drug products and vaginal antifungal products. U.S. Department of Health and Human Services.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
4. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Part 333: Topical antimicrobial drug products for over-the-counter human use. U.S. Government Publishing Office.